PHI with Central core disease
How does this condition affect your private health insurance?
Central core disease (CCD), or Central-core-Krankheit, is a rare, inherited neuromuscular disorder classified as a congenital myopathy. It is primarily caused by mutations in the RYR1 gene, affecting skeletal muscle function. Characterized by muscle weakness, hypotonia, and delayed motor milestones, symptoms typically appear at birth or in early childhood. A defining feature seen on muscle biopsy is the presence of 'central cores' in muscle fibers. While generally non-progressive, individuals may experience varying degrees of weakness, often affecting proximal muscles. Susceptibility to malignant hyperthermia is a significant associated risk.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Lifelong, manifesting from birth or early infancy.
Duration of Illness (Lifetime)
Lifelong chronic condition.
Cost of Treatment (Initial)
High (initial diagnosis, genetic testing, physical therapy, assistive devices, specialist consultations).
Cost of Treatment (Lifetime)
Very high (ongoing physical and occupational therapy, respiratory support, orthopedic interventions, assistive technologies, regular specialist follow-ups).
Mortality Rate
Low for mild to moderate forms; increased in severe forms due to respiratory complications or malignant hyperthermia.
Risk of Secondary Damages
High (scoliosis, joint contractures, respiratory insufficiency, fatigue, potential psychological impact).
Probability of Full Recovery
Extremely low (no cure, management focuses on symptom control and improving function).
Underlying Disease Risk
Moderate (strong association with malignant hyperthermia susceptibility; otherwise, it is often the primary diagnosis rather than an underlying condition).